EIT Health launches two funding calls for innovative health projects Blog Post

EIT Health has lunched two funding initiatives: the grants Headstart and Proof of Concept and the Business Plan Aggregator program. As part of the EIT Health accelerator, both ideas are geared to innovative business ideas, SMEs, spin-offs and start-up committed to the social challenges defined by EIT´s principles: promoting a healthy lifestyle, supporting active ageing and improving quality of life through better healthcare. EIT Health Spain is based at the Barcelona Science Park (PCB) and at presently brings together 18 leading public and private organizations in the three areas of the innovation triangle: research, education and business creation.

 

The turnonver of the 734 companies of the BioRegion amounts to 7% of Catalonia´s GDP Blog Post

The life sciences and healthcare sector of Catalonia gathers 734 companies with a turnover of 14.360 million euros, 7% of Catalonia’s GDP and employs 42,133 workers. These are some of the data yielded by the 2015 Biocat Report, presented last Thursday at the Palau de la Generalitat, which brought more than 200 politicians, business people and figures from academia and science. The event was presided over by the President of the Government of Catalonia, Carles Puigdemont, with the participation of Albert Barberà, CEO at Biocat, the organization that coordinates and promotes the health and life sciences sector in Catalonia, and Ella Korets-Smith, executive director of TO Health!, the Toronto´s life science cluster. 

 

IDP Pharma closes a funding round for 2 million euros Blog Post

IDP Pharma, founded in 2015 and with headquarters at the Barcelona Science Park (PCB) has raised, during its first operative year, over 2 million euros from public and private capital. The biopharmaceutical company –specializes in the development of drugs for cancer treatment directed to a new class of therapeutic targets: IDPs– will appoint this capital to continue the preclinical development of their most advanced products: two first-in-class molecules with antitumor activity for Multiple Myeloma, the second most common blood cancer

 

Mundipharma-Purdue reach a new deal to in-licence from Esteve full global rights for novel first-in-class AS1 for the management of pain Blog Post

Mundipharma its independent associated company Purdue Pharma today announced that, following completion of Phase II studies, they have exercised their option and taken over full responsibility from Laboratorios Esteve for the clinical, regulatory and commercial development of a potential first-in-class sigma-1 antagonist (AS1 o MR309/E-52862). In June 2012, Esteve has moved its Center for Drug Discovery and Preclinical Development to the Barcelona Science Park (PCB) in an attempt to shorten development time and speed up the arrival to market of innovative new drugs. 

 

Researchers froms IBEC and UB have collaborated in the definition of a new kind of indicators for bacterial virulence Blog Post

Researchers and the Institute for Bioengineering of Catalonia (IBEC) and the University of Barcelona (UB) together with their collaborators from the University of Santiago de Compostela (USC), the Institute of Medical Microbiology and Hygiene (University of Lübeck) and German Center for Infection Research (DZIF) have determined a new kind of indicators for bacterial virulence which can help detect and preventing infection outbreaks caused by Escherichia coli.

 

Intelligent Pharma wins the award CaràcterEmpresa to Innovation in Catalonia Blog Post

Intelligent Pharma, a company based at the Barcelona Science Park  (PCB), has won the Premi CaràcterEmpresa award in the category of Innovation among 14 companies from around Catalonia and has been selected to take part in the nation-wide final phase, that will take place this coming June. The CaràcterEmpresa awards are promoted by CaixaBank and by the Spanish Confederatiion of Business Organizations (CEOE) in the Catalan edition, also promoted by Foment del Treball, the institution representing the interests of Catalan industry and business.

Esteve and the Barcelona Science Park strengthen their collaboration for the discovery of new analgesic agents Blog Post

Esteve and the Barcelona Science Park (PCB) have decided to strengthen their collaboration in the field of Discovery of new molecular compounds with analgesic properties through the creation of the ESTEVE-PCB Joint Research Unit. This Unit based at the PCB, at the University of Barcelona campus, is intended to potentiate synergies in the field of chronic pain, a medical need that is not yet fully covered by currently available therapies.     

 

Mind the Byte launches six new software to accelerate drug discovery Blog Post

In line with the ground-breaking pay-per-use philosophy, Mind the Byte has launched six new programs for computational drug design on their SaaS platform (Software as a Service), which the company has been marketing since 2011. The new software expands the services currently on offer and helps cut drug-development time and costs up to 30% for companies and researchers. The products were launched at prices that adapt to the needs of each user.

 

Cebiotex opens a second crowdfunding round for the development of nanofiber tissues against cancer Blog Post

After having succesfully closed a first crowfunding round of 300,000 euros in just 11 days, Cebiotex, a spin-off of the Universitat Politècnica de Catalunya (UPC) and the Sant Joan de Déu-Barcelona Children’s Hospital, located at the Barcelona Science Park (PCB), has launched a second round of  300,000 euros, managed, once more, by European biotech crowdfunding platform CapitalCell. The company will allocate the resources obtained to expedite the development of an innovative system to administer antitumor drugs – a biodegradable nanofiber tissue for the local treatment of cancer- while ensuring that these new drugs are made available not only for adult patients but also for pediatric oncological patients 

 

Eugin grows its business to 14,000 treatments per year Blog Post

Eugin Clinic performed 13,885 assisted reproduction treatments in 2015, which places it as one of the European leaders in the sector. The international centre, which has its basic research laboratory at the Barcelona Science Park (PCB), performs 10% of the treatments by means of egg donation from all over Europe and their success rates, which are verified by the prestigious German certification agency, TÜV, confirm that 9 in10 women achieve pregnancy. Eugin is also undertaking a large number of scientific projects with leading research centres and six European universities, including the University of Barcelona (UB).